Prosight Management
Latest statistics and disclosures from Prosight Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NKTR, BSX, JANX, PRCT, Galapagos Nv-, and represent 40.55% of Prosight Management's stock portfolio.
- Added to shares of these 10 stocks: BSX (+$37M), WGS (+$30M), ALNY (+$20M), ALKS (+$18M), STTK (+$17M), JANX (+$16M), Galapagos Nv- (+$14M), PRCT (+$14M), NKTR (+$13M), ABVX (+$9.8M).
- Started 16 new stock positions in ANTX, ICUI, IRTC, VKTX, COYA, ISRG, NVCR, OMER, ALKS, RGNX. SDGR, UPB, IMRX, TMDX, EBS, PVLA.
- Reduced shares in these 10 stocks: , , , ROIV (-$12M), AVTR (-$10M), LH (-$8.7M), CON (-$8.3M), MGTX (-$5.0M), TECX, CDNA.
- Sold out of its positions in FOLD, AVTR, BBIO, CDNA, LH, Select Medical Holdings Corporation, TEM, ICLR.
- Prosight Management was a net buyer of stock by $133M.
- Prosight Management has $610M in assets under management (AUM), dropping by 26.01%.
- Central Index Key (CIK): 0001617201
Tip: Access up to 7 years of quarterly data
Positions held by Prosight Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Prosight Management
Prosight Management holds 46 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nektar Therapeutics Com New (NKTR) | 8.7 | $53M | +32% | 735k | 71.95 |
|
| Boston Scientific Corporation (BSX) | 8.2 | $50M | +278% | 796k | 62.75 |
|
| Janux Therapeutics (JANX) | 8.1 | $49M | +48% | 3.6M | 13.90 |
|
| Procept Biorobotics Corp (PRCT) | 8.0 | $49M | +40% | 1.9M | 25.01 |
|
| Galapagos Nv Spon Adr | 7.6 | $47M | +44% | 1.6M | 30.00 |
|
| Genedx Holdings Corp Com Cl A (WGS) | 5.5 | $34M | +851% | 524k | 64.22 |
|
| Shattuck Labs (STTK) | 5.3 | $32M | +110% | 5.0M | 6.43 |
|
| Adc Therapeutics Sa SHS (ADCT) | 5.1 | $31M | -2% | 8.3M | 3.75 |
|
| Kura Oncology (KURA) | 4.5 | $27M | +32% | 3.4M | 8.13 |
|
| Alnylam Pharmaceuticals (ALNY) | 4.1 | $25M | +344% | 76k | 330.87 |
|
| Meiragtx Holdings (MGTX) | 3.7 | $23M | -18% | 2.6M | 8.66 |
|
| Alkermes SHS (ALKS) | 3.0 | $18M | NEW | 514k | 35.36 |
|
| Syndax Pharmaceuticals (SNDX) | 2.9 | $18M | +15% | 770k | 23.36 |
|
| Veeva Sys Cl A Com (VEEV) | 2.5 | $15M | -4% | 87k | 175.66 |
|
| Zymeworks Del (ZYME) | 2.2 | $14M | 539k | 25.04 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 2.1 | $13M | +33% | 350k | 36.32 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.9 | $12M | +517% | 105k | 111.35 |
|
| Concentra Group Holdings Par Common Stock (CON) | 1.8 | $11M | -43% | 506k | 21.45 |
|
| Terns Pharmaceuticals (TERN) | 1.7 | $11M | +112% | 202k | 52.72 |
|
| Phreesia (PHR) | 1.5 | $9.2M | +12% | 1.1M | 8.38 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 1.5 | $8.9M | +163% | 2.2M | 4.14 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $6.5M | 697k | 9.39 |
|
|
| Schrodinger (SDGR) | 1.0 | $5.8M | NEW | 511k | 11.36 |
|
| Emergent BioSolutions (EBS) | 0.9 | $5.3M | NEW | 639k | 8.30 |
|
| Roivant Sciences SHS (ROIV) | 0.8 | $5.0M | -71% | 180k | 27.70 |
|
| Orthopediatrics Corp. (KIDS) | 0.8 | $4.8M | +121% | 302k | 15.87 |
|
| Immunovant (IMVT) | 0.7 | $4.4M | -27% | 176k | 24.84 |
|
| ICU Medical, Incorporated (ICUI) | 0.6 | $3.5M | NEW | 28k | 129.15 |
|
| Tectonic Therapeutic (TECX) | 0.4 | $2.5M | -66% | 80k | 30.91 |
|
| Rocket Pharmaceuticals (RCKT) | 0.4 | $2.4M | -8% | 684k | 3.58 |
|
| Upstream Bio (UPB) | 0.4 | $2.2M | NEW | 241k | 9.00 |
|
| Pliant Therapeutics (PLRX) | 0.3 | $2.1M | +7% | 1.7M | 1.26 |
|
| Omeros Corporation (OMER) | 0.3 | $1.8M | NEW | 175k | 10.56 |
|
| Intuitive Surgical Com New (ISRG) | 0.3 | $1.8M | NEW | 4.0k | 460.99 |
|
| An2 Therapeutics (ANTX) | 0.3 | $1.8M | NEW | 516k | 3.42 |
|
| Adicet Bio Com New (ACET) | 0.3 | $1.7M | 250k | 6.81 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.3 | $1.7M | NEW | 200k | 8.38 |
|
| Coya Therapeutics Common Stock (COYA) | 0.3 | $1.7M | NEW | 420k | 3.94 |
|
| Viking Therapeutics (VKTX) | 0.2 | $1.5M | NEW | 45k | 32.54 |
|
| Irhythm Technologies (IRTC) | 0.2 | $1.2M | NEW | 10k | 118.02 |
|
| TrueBlue (TBI) | 0.2 | $974k | -43% | 249k | 3.91 |
|
| Immuneering Corp Class A Com (IMRX) | 0.1 | $650k | NEW | 123k | 5.27 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.1 | $623k | NEW | 5.0k | 124.65 |
|
| Novocure Ord Shs (NVCR) | 0.1 | $549k | NEW | 50k | 10.90 |
|
| Rein Therapeutics Com New (RNTX) | 0.1 | $535k | -7% | 412k | 1.30 |
|
| Transmedics Group (TMDX) | 0.1 | $497k | NEW | 5.0k | 99.41 |
|
Past Filings by Prosight Management
SEC 13F filings are viewable for Prosight Management going back to 2017
- Prosight Management 2026 Q1 filed May 15, 2026
- Prosight Management 2025 Q4 filed Feb. 13, 2026
- Prosight Management 2025 Q3 filed Nov. 14, 2025
- Prosight Management 2025 Q2 filed Aug. 14, 2025
- Prosight Management 2025 Q1 filed May 15, 2025
- Prosight Management 2024 Q4 filed Feb. 14, 2025
- Prosight Management 2024 Q3 filed Nov. 14, 2024
- Prosight Management 2024 Q2 filed Aug. 14, 2024
- Prosight Management 2024 Q1 filed May 15, 2024
- Prosight Management 2023 Q3 filed Nov. 14, 2023
- Prosight Management 2023 Q2 filed Aug. 14, 2023
- Prosight Management 2023 Q2 restated filed Aug. 14, 2023
- Prosight Management 2023 Q1 filed May 12, 2023
- Prosight Management 2022 Q4 filed Feb. 14, 2023
- Prosight Management 2022 Q3 filed Nov. 14, 2022
- Prosight Management 2022 Q2 filed Aug. 12, 2022